Levit Alex C. 4

What Happened

• Alex C. Levit, Chief Legal Officer and Corporate Secretary of Context Therapeutics (CNTX), was granted a derivative award of 270,000 shares on February 19, 2026. The Form 4 reports the grant at $0.00 (derivative instrument) and shows no immediate cash transaction or sale.

Key Details

• Transaction date: 2026-02-19; Filed with SEC: 2026-02-23 (filing appears timely).
• Reported amount: 270,000 shares (derivative award) at $0.00 in the filing.
• Shares owned after transaction: Not disclosed in the provided excerpt of the Form 4.
• Footnote: The option vests over four years — 25% on Feb 19, 2027, then monthly installments over the next three years, subject to continued service.
• Nature: This is an equity compensation grant (option award), not an open-market purchase or sale.

Context

• This grant is a standard equity compensation mechanism to align executive incentives; it does not represent an immediate purchase or sale of stock. Because the award vests over time, economic ownership depends on future vesting and any exercise terms not fully detailed in the excerpt.